BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
BioNTech and Bristol Myers reported interim Phase 2 results from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) plus chemotherapy in previously untreated advanced NSCLC. The companies said the data showed encouraging anti-tumor activity with high response rates across squamous and non-squamous tumors and across PD-L1 levels. Separately, UBS upgraded BioNTech to Buy and raised its price target to $135 from $117.
Interim ROSETTA Lung-02 efficacy signal and a concurrent UBS upgrade can support near-term sentiment and re-rate expectations for BNTX’s oncology pipeline.
BioNTech reported interim Phase 2 ROSETTA Lung-02 data showing “encouraging anti-tumor activity” across NSCLC subtypes and PD-L1 levels.
Bias to the upside on continued clinical follow-through; near-term volatility likely around additional trial updates.
Background
ROSETTA Lung-02 is a global Phase 2/3 trial evaluating pumitamig (PD-L1xVEGF-A bispecific) plus chemotherapy in previously untreated advanced NSCLC.
Why it matters
The article highlights encouraging response rates across squamous/non-squamous and PD-L1 strata, supporting continued investigation; it also notes a UBS upgrade and price-target increase.
Market relevance
Traders may reassess BNTX’s oncology pipeline prospects based on interim efficacy language and sell-side sentiment support from the UBS upgrade.
Market effects
Positive PD-L1xVEGF-A bispecific efficacy framing can lift sentiment for immuno-oncology trial read-throughs, though it’s company-specific interim data.
Limited direct regional impact; primarily US-listed biotech sentiment.
Global NSCLC trial results can influence international biotech risk appetite, but no cross-company deal/regulatory action is cited.
Alternative perspectives
Interim Phase 2 efficacy signals may not translate into durable survival benefit; without final endpoints, the market may over-discount the magnitude of benefit.
Key details like durability, safety/tolerability, and statistical strength versus control are not provided here, which can cap upside if later data disappoint.
Key entities
- companyBioNTech SE
Sponsor of the ROSETTA Lung-02 interim Phase 2 data and recipient of a UBS upgrade to Buy with a higher price target.
- companyBristol Myers Squibb
Co-announced the interim ROSETTA Lung-02 Phase 2 data with BioNTech.
- clinical_trialROSETTA Lung-02
Global Phase 2/3 trial assessing pumitamig plus chemotherapy in advanced NSCLC.
